Leading researches say that chronic diseases can be treated with the help of nucleoside polymerase inhibitor, R1626, along with standard hepatitis C therapy.
They point out a marked increase in antiviral effect in patients who were administered ribavirin with a combination of R1626 and peginterferon alfa-2a.
Out of more than 100 patients having HCV genotype 1, 21 were given 1500 mg R1626 two times each day, which was combined with alpha-2a (peginterferon). Thirty-two were given 3000 mg R1626 two times in a day with the same subsidiary ingredient. 31 were given 1500 mg R1626 two times in a day along with ribavirin and peginterferon alpha-2a. The remaining was given ribavirin with peginterferon alpha-2a.
After 4 weeks, it was found that HCV RNA is narrowly found in 29 per cent of the 21 patients. HCV RNA was barely visible in 69 percent of the 32 patients who were given 3000 mg of R1626, and it was hardly visible in 74 per cent among the 31 patients who were given 1500 mg of R1626 twice a day along with peginterferon alpha-2a and ribavirin. This only shows that R1626 has great impact in reducing the HCV RNA.
In another study, it was found that antiviral activities increased with dosage in chronic hepatitis C patients.
The copyright of the published articles in healthtip.info completely belongs to the website and republishing of article without permission is strictly against website policy. For any assistance in please contact the admin.
No comments yet.
RSS feed for comments on this post. TrackBack URL